NOVARTIND.NS Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Okt 2023 @ 12:00):

Stats
Tagesvolumen	11 685.00
Durchschnittsvolumen	5 696.00
Marktkapitalisierung	16.64B
EPS	INR10.76 ( 2024-02-13 )
Nächstes Ertragsdatum	( INR0 ) 2024-05-10
Last Dividend	INR37.50 ( 2023-07-20 )
Next Dividend	INR0 ( N/A )
P/E	21.75
ATR14	INR12.22 (1.82%)

Volumen Korrelation

Lang: 0.74 (moderate)

Kurz: 0.00 (neutral)

Signal:(25.341) Neutral

Novartis India Limited Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Novartis India Limited Korrelation - Währung/Rohstoff

0.80
( moderate )

0.82
( strong )

-0.13
( neutral )

0.86
( strong )

0.35
( neutral )

-0.69
( moderate negative )

Novartis India Limited Finanzdaten

Annual	2022
Umsatz:	INR3.79B
Bruttogewinn:	INR1.77B (46.75 %)
EPS:	INR41.86

FY	2022
Umsatz:	INR3.79B
Bruttogewinn:	INR1.77B (46.75 %)
EPS:	INR41.86

FY	2022
Umsatz:	INR3.88B
Bruttogewinn:	INR2.06B (53.18 %)
EPS:	INR-1.510

FY	2021
Umsatz:	INR3.66B
Bruttogewinn:	INR2.16B (59.07 %)
EPS:	INR8.46

Financial Reports:

No articles found.

Novartis India Limited Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR10.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR37.50 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Novartis India Limited Dividend Information - Dividend Junior

Dividend Sustainability Score: 4.04 - low (34.25%) | Divividend Growth Potential Score: 3.98 - Decrease likely (20.47%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR10.00	2021-08-17
Last Dividend	INR37.50	2023-07-20
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	3	--
Total Paid Out	INR57.50	--
Avg. Dividend % Per Year	2.07%	--
Score	2.56	--
Div. Sustainability Score	4.04
Div.Growth Potential Score	3.98
Div. Directional Score	4.01	--

Next Divdend (Est)
(2024-07-01)

INR65.00 Estimate 3.06 %

Dividend Stability

0.24 Very Poor

Dividend Score

2.56

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2021	INR10.00	1.45%
2022	INR10.00	1.28%
2023	INR37.50	5.57%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
SUNPHARMA.NS	Dividend Junior	2023-07-28	Semi-Annually	29	0.77%
NAVA.NS	Dividend Knight	2023-07-24	Annually	23	2.35%
HONAUT.NS	Dividend Junior	2023-08-03	Annually	21	0.15%
CARBORUNIV.NS	Dividend Junior	2023-07-25	Semi-Annually	23	0.33%
ROHLTD.NS	Dividend Junior	2023-09-15	Sporadic	19	0.20%
LAURUSLABS.NS	Dividend Knight	2023-05-10	Semi-Annually	8	0.35%
FOSECOIND.NS	Dividend Knight	2023-05-17	Annually	22	0.68%
APOLLO.NS	Dividend Junior	2023-09-22	Annually	7	0.79%
TCI.NS	Dividend Junior	2023-07-25	Semi-Annually	23	0.70%
OBEROIRLTY.NS	Dividend Junior	2023-06-21	Sporadic	14	0.19%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.289	1.500	4.21	6.32	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.129	1.500	9.67	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	70.26	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	2.16	2.00	9.28	10.00	[0 - 30]
freeCashFlowPerShareTTM	2.16	2.00	8.92	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.427	1.000	6.21	6.21	[0.2 - 0.8]
operatingProfitMarginTTM	0.347	1.000	5.06	5.06	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				4.04

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	17.42	1.000	8.34	0	[1 - 100]
returnOnEquityTTM	0.129	2.50	9.79	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	2.16	2.00	9.28	10.00	[0 - 30]
dividendYielPercentageTTM	5.56	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	2.16	2.00	9.28	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.148	1.500	-4.32	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0162	1.000	-2.10	0	[0.1 - 0.5]
Total Score				3.98

Novartis India Limited

Novartis India Limited operates as a healthcare company in India. It offers pharmaceutical products in the areas of bone and pain, calcium portfolio, gynecology, and neurosciences, as well as generics products in the areas of gynecology, anti-TB, and anti-infectives. The company provides central nervous system products under the Tegrital and Exelon brands; pain and inflammation products under the Voveran brand; and transplantation/immunology products under the Simulect, Certican, Myfortic, and Sandimmun Neoral brands. The company was incorporated in 1947 and is headquartered in Mumbai, India. Novartis India Limited is a subsidiary of Novartis AG.